Healthcare / Medical DevicesLSE
$57.80
-0.20 (-0.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $13.9M · quality 82.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$243M
P/E
28.9x
↑EV/EBITDA
1608.9x
↑ROE
10.4%
↑Gross Margin
69.2%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+15.9%
FCF CAGR
+28.2%
FCF margin
28.5%
FCF / Net income
1.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $48.7M · net income $7.0M · FCF $13.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $48.7M | $48.7M | $41.8M | $36.8M | $31.3M |
| Net Income | $7.0M | $7.0M | $3.7M | $10.7M | $16.1M |
| EBITDA | $15.3M | $15.3M | $12.1M | $8.6M | $15.2M |
| EPS | 0.02 | 0.02 | 0.01 | 0.02 | 0.04 |
| Gross Margin | 69.2% | 69.2% | 72.2% | 72.0% | 70.9% |
| Operating Margin | 22.0% | 22.0% | 18.4% | 12.5% | 5.8% |
| Net Margin | 14.4% | 14.4% | 8.9% | 29.1% | 51.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.01 | 0.01 |
| Current Ratio | 3.81 | 3.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $13.9M | $13.9M | $16.2M | $11.3M | $6.6M |
| Returns | |||||
| ROE | 10.4% | 10.4% | 6.2% | 12.8% | 19.7% |
| Valuation | |||||
| P/E | 28.90 | 28.90 | 7590.36 | 2684.87 | 1038.57 |
| EV/EBITDA | 1608.91 | 1608.91 | 2332.86 | 3336.06 | 1097.54 |
| P/B | 364.43 | 364.43 | 474.57 | 342.59 | 203.92 |
| Growth & Yield | |||||
| Revenue Growth | 16.5% | 16.5% | 13.6% | 17.6% | — |
| EPS Growth | 97.6% | 97.6% | -65.1% | -34.4% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
578.8%
EPS terminal req.
$5.13
Spread vs growth
-481.2%
5Y implied EPS CAGR
227.8%
EPS terminal req.
$6.21
Spread vs growth
-130.2%
10Y implied EPS CAGR
89.9%
EPS terminal req.
$9.99
Spread vs growth
7.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.9%
Start / end P/E
8771.1x → 3524.4x
EPS bridge
0.01 → 0.02
Residual
-58.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.